Prognostic Model of Hypertension

Condition(s) studied

Investigational drug(s) / intervention(s)

Standard therapy: Individualized blood pressure reduction program

Study summary

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Eligibility

Primary outcome measure(s)

• Resistant hypertension — 10 years of follow-up Resistant hypertension occurred during this period
• Death (all-cause mortality, mortality from hypertension complications) — 10 years of follow-up deaths occurred during this period

Trial sites (1)

More Xinjiang Medical University trials in China

Other trials for the same condition